

SYMDEKO (tezacaftor/ivacaftor) PRIOR AUTHORIZATION FORM

For **Symdeko** and **Quantity Limits/Daily Dose Limits** prior authorization guidelines, see <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # of pages: _____	
Name of office contact:		Prescriber name:	
Contact's phone number:		Specialty:	
LTC facility contact/phone:		State license #:	
		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Medication requested: Symdeko	Dosage form: <input type="checkbox"/> tablet <input type="checkbox"/> other: _____	Strength:	
Directions:		Qty:	Refills:
Diagnosis:		DX code (required):	
Specialty Pharmacy Drug Program: Symdeko is part of the DHS Specialty Pharmacy Drug Program and is only available from one of the two DHS specialty pharmacies – Walgreen's Specialty Pharmacy .			
Is the medication being prescribed by, or in consultation with, a pulmonologist or cystic fibrosis specialist?		<input type="checkbox"/> Yes	<input type="checkbox"/> No

Initial requests

1. Does the beneficiary have results of an FDA-cleared cystic fibrosis (CF) mutation test that shows the presence of a mutation(s) in the CFTR gene as noted in the package labeling?	<input type="checkbox"/> Yes – <i>Submit documentation of results.</i> <input type="checkbox"/> No
2. Does the beneficiary have documentation of a baseline (pre-treatment) FEV ₁ ?	<input type="checkbox"/> Yes – <i>Submit documentation of results.</i> <input type="checkbox"/> No
3. Does the beneficiary have lab results of baseline (pre-treatment) ALT and AST (liver function tests/LFTs)?	<input type="checkbox"/> Yes – <i>Submit documentation of results.</i> <input type="checkbox"/> No
4. Will the beneficiary have repeat liver function tests (ALT, AST, bilirubin) every 3 months during the first year of treatment and annually thereafter?	<input type="checkbox"/> Yes – <i>Submit chart documentation.</i> <input type="checkbox"/> No
5. Does the beneficiary have liver disease or liver impairment?	<input type="checkbox"/> Yes <i>Submit documentation of degree of impairment.</i> <input type="checkbox"/> No
6. Is the beneficiary taking any of the following medications? <u>Check all that apply.</u> <input type="checkbox"/> strong P450 3A inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, etc.) <input type="checkbox"/> moderate or strong P450 3A inhibitor (e.g., azole antifungal, macrolide antibiotic, ritonavir, etc.)	<input type="checkbox"/> Yes <i>Submit beneficiary's complete current medication list.</i> <input type="checkbox"/> No

Renewal requests

1. Does the beneficiary have recent lab results of liver function tests (ALT, AST, bilirubin)? <i>Note: Testing should be completed every 3 months for the first year of therapy and annually thereafter.</i>	<input type="checkbox"/> Yes – <i>Submit documentation of results.</i> <input type="checkbox"/> No
2. Does the beneficiary have liver disease or liver impairment?	<input type="checkbox"/> Yes <i>Submit documentation of degree of impairment.</i> <input type="checkbox"/> No
3. Is the beneficiary receiving clinical benefit from Symdeko?	<input type="checkbox"/> Yes <i>Submit documentation of beneficiary's clinical response.</i> <input type="checkbox"/> No
4. Is the beneficiary taking any of the following medications? <u>Check all that apply.</u> <input type="checkbox"/> strong P450 3A inducer (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, etc.) <input type="checkbox"/> moderate or strong P450 3A inhibitor (e.g., azole antifungal, macrolide antibiotic, ritonavir, etc.)	<input type="checkbox"/> Yes <i>Submit beneficiary's complete current medication list.</i> <input type="checkbox"/> No

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.